

## Electronic Supplementary Information for

# Evolution-guided engineering of nonribosomal peptide synthetase adenylation domains

Max Crüsemann,<sup>a</sup> Christoph Kohlhaas,<sup>a</sup> and Jörn Piel<sup>\*a,b</sup>

### LEGENDS

**Figure S1:** Alignment of the A domains of HrmO1-P3 and CdaPSI-A5/H6. Black bars indicate the selected fusion sites.

**Figure S2:** SDS-PAGE analysis (15%, Tris/Tricine) of the expressed and Ni-purified A domain/MbtH complexes HrmO1<sub>A</sub>, HrmO3<sub>A</sub>, HrmO4<sub>A</sub>, HrmP1<sub>A</sub>, HrmP2<sub>A</sub>, O2f<sub>A</sub>, O4f<sub>A</sub>, P2f<sub>A</sub>, A5f<sub>A</sub>, H6f<sub>A</sub>, coeluted with HrmR. A5f<sub>x</sub> shows a coelution of A5f<sub>A</sub> with CdaX. M=Marker.

**Figure S3:** SDS-PAGE analysis (15%, Tris/Tricine) of the FPLC-purified A domain/HrmR complexes HrmO1<sub>A</sub>, HrmO2<sub>A</sub>, HrmO3<sub>A</sub>, O2f<sub>A</sub>, HrmP1<sub>A</sub>, HrmP3<sub>A</sub>. M=Marker.

**Figure S4:** Results of the  $\gamma^{18}\text{O}_4$ -ATP assay for **A**, HrmO1<sub>A</sub>; **B**, HrmO2<sub>A</sub>; **C**, HrmO3<sub>A</sub>; **D**, HrmO4<sub>A</sub>; **E**, HrmP1<sub>A</sub>; **F**, HrmP2<sub>A</sub> (black); **G**, HrmP3<sub>A</sub>. The preferred substrate is equal 100%. X-axis: % relative activation.

**Table S1:** Sequences of the primers used in this study. Inserted restriction sites are underlined, complementary parts to *hrmO3* are in italics.

**Table S2:** Obtained C- and TM-scores generated by I-TASSER for HrmO3<sub>A</sub> and the engineered A domains. The quality parameters of the created models are in the same range as HrmO3<sub>A</sub>, indicating sufficient quality of the models.







Figure S1: Alignment of the A domains of HrmO1-P3 and CdaPSI-A5/H6. Black bars indicate the selected fusion sites.



**Figure S2:** SDS-PAGE analysis (15%, Tris/Tricine) of the expressed and Ni-NTA affinity-purified A domain/MbtH complexes HrmO1<sub>A</sub>, HrmO3<sub>A</sub>, HrmO4<sub>A</sub>, HrmP1<sub>A</sub>, HrmP2<sub>A</sub>, O2f<sub>A</sub>, O4f<sub>A</sub>, P2f<sub>A</sub>, A5f<sub>A</sub>, H6f<sub>A</sub>, coeluted with HrmR. A5f<sub>x</sub> shows a coelution of A5f<sub>A</sub> with CdaX. M=Marker




**Figure S3:** SDS-PAGE analysis (15%, Tris/Tricine) of the FPLC-purified A domain/HrmR complexes HrmO1<sub>A</sub>, HrmO2<sub>A</sub>, HrmO3<sub>A</sub>, O2f<sub>A</sub>, HrmP1<sub>A</sub>, HrmP3<sub>A</sub>. M=Marker




**Figure S4:** Results of the  $\gamma^{18}\text{O}_4$ -ATP assay for **A**, HrmO1<sub>A</sub>; **B**, HrmO2<sub>A</sub>; **C**, HrmO3<sub>A</sub>; **D**, HrmO4<sub>A</sub>; **E**, HrmP1<sub>A</sub>; **F**, HrmP2<sub>A</sub> (black); **G**, HrmP3<sub>A</sub>. The preferred substrate is equal 100%. Y-axis: % relative activation.

D



E



F




Figure S4, continued.




Figure S4, continued.

**Table S1:** Sequences of the primers used in this study. Inserted restriction sites are underlined, complementary parts to *hrmO3* are in italics. Pairs O1F/O1R to P3F/P3R were used to amplify DNA regions encoding A domains O1<sub>A</sub> to P3<sub>A</sub>.

O1F:	AAAGAATTCAGCCGGCTGGACGTGGTTA
O1R:	AAAAAGCTTTCACCTCCTCGGGCGTACG
O2F:	AAAGAATTCGGCGACGTCGACGTCCTG
O2R:	AAAAAGCTTTCATTCCTCGGGGCGTCGCG
O3F:	AAAGAATTCGGCCGGCTGGACGTCGTC
O3R:	AAAAAGCTTTCACCTCCTCCCGCGGTGTGCG
O4F:	AAAGAATTCCTGAATCTTGACATCGTCACTG
O4R:	AAAAAGCTTTCACCTCCTCGGGCGTACG
P1F:	AAAGAATTCGGCCGGCTGGACGTCGT
P1R:	AAAAAGCTTTCACCTCCTCGCGGGTACGCG
P2F:	AAACAATTGGGCCGCATCGACCTGGTC
P2R:	AAAAAGCTTTCACCTCCTCGCCGGTACG
P3F:	AAAGAATTCGGTTCGTCGGGCTGTTGT
P3R:	AAAAAGCTTTCACGCCTCCTCGGGGTGG
cdaXF:	AAAAAACATATGAGTAATCCCTTCGACGAC
cdaXR:	AAA AACTCGAGTCCGGTCAGTTGCCGGTG
hrmRF:	AAAAAACATATGCGAGATCGAGAAAAGAATGGA
hrmFR:	AAAAAAGAGCTCTCATGCCGCGCTCCCTTC
O3_nestedF:	CTGGACGTCGTCACGGCG
O3_nestedR:	CTCCTCCCGCGGTGTGCG
O3_leftF:	AAAGAATTCGCTTTCGCGGCCGATCCG
O3_leftR:	ATGCGAAACCACCACACCT
O3_rightF:	TACGGGGCGACGGAGGTG
O3_rightR:	AAAAAGCTTACACCGACCCGCTCCAGC
O4_insertF:	<i>AAGGTGTGGTGGTTTCGCATGCGGGTCTGGGGAATTTG</i>
O4_insertR:	<i>CGTCACCTCCGTCGCCCGTACCCGTTTCAGCAACCGCCG</i>
O2_insertF:	<i>AAGGGTGTGGTGGTTTCGCATCGGAACGTCGTGCGCCTCT</i>
O2_insertR:	<i>CGTCACCTCCGTCGCCCGTACATGTTGACCAGGGTCGGA</i>



P2\_insertF: AAGGGTGTGGTGGTTTCGCATAGGGCCGTCTGCGCGTTG

P2\_insertR: *CGTCACCTCCGTCGCCCCGTAGACGTGCACCACCAGCGT*

Asp\_insertF: AAGGGTGTGGTGGTTTCGCATCACGCCCTGGCCACCTAC

Asp\_insertR: *CGTCACCTCCGTCGCCCCGTAGGCGTTGATGATCTGGGCG*

HPG\_insertF: *AAGGGTGTGGTGGTTTCGCATCGCGGGGTCGTGGACCTG*

HPG\_insertR: *CGTCACCTCCGTCGCCCCGTACAGGTGACGCAGTACGATCC*

**Table S2:** Obtained C- and TM-scores generated by I-TASSER for HrmO3<sub>A</sub> and the engineered A domains. The quality parameters of the created models are in the same range as HrmO3<sub>A</sub>, indicating sufficient quality of the models.

<b>Protein</b>	<b>C-score</b>	<b>TM-Score</b>
HrmO3 <sub>A</sub>	0,96	0,84
O2f <sub>A</sub>	0,81	0,82
O4f <sub>A</sub>	0,54	0,79
P2f <sub>A</sub>	0,51	0,78
A5f <sub>A</sub>	0,77	0,82
H6f <sub>A</sub>	0,81	0,82